Who Is a Good Candidate for Infusion Therapy
In recent years, glutathione has gained significant attention in aesthetic dermatology for its skin-brightening and antioxidant benefits
This milestone reinforces Eccogenes position as an innovator in advancing novel, differentiated oral therapies for cardiometabolic diseases with broad commercial potential. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, commented: The start of this Phase 1b trial in China marks an important milestone in the extensive clinical program for AZD5004/ECC5004, an oral small molecule GLP-1RA which has significant potential as part of our extensive CVRM portfolio
Pathogen molecular pattern receptor agonists: treating cancer by mimicking infection
Increased risk of diarrhea-predominant irritable bowel syndrome (IBS-D) Increased insulin resistance and glucose intolerance, contributing to elevated blood glucose Poor wound healing, altered taste and smell, and changes in cognitive function, particularly in older adults How common is zinc deficiency
Persistent or severe gastrointestinal symptoms warrant medical review, as dose adjustment or temporary treatment interruption may be necessary